TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine Used for Sedation During Elective Awake Fiberoptic Intubation
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine versus placebo used for sedation during elective awake fiberoptic intubation.


Options:
A: N/A
B: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Placebo (PBO); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (PBO)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl 9/00 | Arm Label: dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Intervention Type: DRUG; Name: NaCl 9/00; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): dexmedetomidine
D: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Brief Summary: The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.


Options:
A: Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine 60mg; Type: OTHER; Interventions: Drug: Duloxetine 60 mg/day | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg/day; Assigned to Arm(s): Duloxetine 60mg
B: Arm Label: Workcoping and IPS; Type: EXPERIMENTAL; Interventions: Behavioral: Workcoping and IPS | Arm Label: Ordinary care by GP or NAV; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ordinary care by GP or NAV | Intervention Type: BEHAVIORAL; Name: Workcoping and IPS; Assigned to Arm(s): Workcoping and IPS | Intervention Type: BEHAVIORAL; Name: Ordinary care by GP or NAV; Assigned to Arm(s): Ordinary care by GP or NAV
C: Arm Label: IPS-MA; Type: EXPERIMENTAL; Interventions: Behavioral: The IPS-MA method | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The IPS-MA method; Assigned to Arm(s): IPS-MA
D: Arm Label: duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Arm Label: fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: paroxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine | Arm Label: sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: sertraline | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): duloxetine | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): paroxetine | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): sertraline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Brief Summary: The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.


Options:
A: Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine: 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine: 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Duloxetine: 60 mg; Type: OTHER; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine: 2.5 mg | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine: 5 mg | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine: 10 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine: 60 mg
C: Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine 60mg; Type: OTHER; Interventions: Drug: Duloxetine 60 mg/day | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg/day; Assigned to Arm(s): Duloxetine 60mg
D: Intervention Type: DRUG; Name: Quetiapine fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma
Brief Summary: The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Treatment medication will be administered as follows: ciclesonide or placebo will be inhaled once daily in the evening. The study consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). The study provides further data on safety and tolerability of ciclesonide.


Options:
A: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo
B: Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Ciclesonide (XRP1526); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma
Brief Summary: The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Treatment medication will be administered as follows: ciclesonide or placebo will be inhaled once daily in the evening. The study consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). The study provides further data on safety and tolerability of ciclesonide.


Options:
A: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo
B: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
D: Arm Label: Reference Strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhaled corticosteroids | Arm Label: Biomarker Strategy; Type: EXPERIMENTAL; Interventions: Drug: Inhaled corticosteroids, Procedure: eNO measurement | Intervention Type: DRUG; Name: Inhaled corticosteroids; Assigned to Arm(s): Biomarker Strategy, Reference Strategy | Intervention Type: PROCEDURE; Name: eNO measurement; Assigned to Arm(s): Biomarker Strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma
Brief Summary: The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Treatment medication will be administered as follows: ciclesonide or placebo will be inhaled once daily in the evening. The study consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). The study provides further data on safety and tolerability of ciclesonide.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
C: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo
D: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones
Brief Summary: This is an 8 week study that compares two medications. One medication is olanzapine (5-20 mg daily) whereas the other medication is an orally disintegrating medication. Both medications are used to treat depressed bipolar patients. The main focus of this study is the comparison of these two medications on gastro-intestinal hormones and weight gain.


Options:
A: Arm Label: Lifestyle intervention to increase physical activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: lifestyle intervention to increase physical activity | Arm Label: waiting control group; Type: NO_INTERVENTION; Interventions: Behavioral: lifestyle intervention to increase physical activity | Intervention Type: BEHAVIORAL; Name: lifestyle intervention to increase physical activity; Assigned to Arm(s): Lifestyle intervention to increase physical activity, waiting control group
B: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle Balance; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Behavioral Weight Loss Program; Assigned to Arm(s): Lifestyle Balance
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: orally-disintegrating olanzapine | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: regular olanzapine | Intervention Type: DRUG; Name: orally-disintegrating olanzapine; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: regular olanzapine; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of escitalopram to an active comparator in severely depressed patients


Options:
A: Arm Label: Duloxetine Hydrochloride (60 mg); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine hydrochloride, Drug: Placebo | Arm Label: Duloxetine Hydrochloride (120 mg); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine hydrochloride, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine hydrochloride; Assigned to Arm(s): Duloxetine Hydrochloride (120 mg), Duloxetine Hydrochloride (60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine Hydrochloride (120 mg), Duloxetine Hydrochloride (60 mg)
B: Arm Label: Early Intervention; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride, Drug: Escitalopram | Arm Label: Delayed Intervention; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride, Drug: Escitalopram | Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): Delayed Intervention, Early Intervention | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Delayed Intervention, Early Intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole (Fixed dose) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole (Titrated dose) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole (Fixed dose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole (Titrated dose); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Double-blind Study of Nitazoxanide Compared to Vancomycin in the Treatment of Clostridium Difficile-associated Disease
Brief Summary: The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).


Options:
A: Arm Label: LFF571 (POC); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: Vancomycin (POC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin (POC) | Arm Label: LFF571 Dose level 1 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: LFF571 Dose level 2 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: LFF571 Dose level 3 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: LFF571 Dose level 4 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Intervention Type: DRUG; Name: LFF571; Assigned to Arm(s): LFF571 (POC), LFF571 Dose level 1 (cohort 2), LFF571 Dose level 2 (cohort 2), LFF571 Dose level 3 (cohort 2), LFF571 Dose level 4 (cohort 2) | Intervention Type: DRUG; Name: Vancomycin (POC); Assigned to Arm(s): Vancomycin (POC)
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: PAR-101/OPT-80 | Intervention Type: DRUG; Name: PAR-101/OPT-80; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: Tolevamer potassium-sodium (GT267-004); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nitazoxanide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: Nitazoxanide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of an Oxidative-Stress-Reducing Strategy Consisting of Pravastatin, Vitamin E and Homocysteine-Lowering on Carotid Intima-Media Thickness in Patients With Mild-to-Moderate Chronic Kidney Disease
Brief Summary: The ATIC study is a randomised, double- blind, placebo-controlled trial in which the effects of oxidative stress-lowering treatment on vascular function and structure are studied in patients with chronic non-diabetic renal failure who are free from manifest arterial occlusive disease. Participants in the trial were randomised to active treatment consisting of add-on therapy with pravastatin, vitamin E and homocysteine-lowering therapy, or to placebo. Subjects not using angiotensin converting enzyme inhibitors (ACE-inhibitors) or angiotensin receptor blockers (ARBs) at inclusion were put on ACE-inhibitors for at least two weeks before the baseline measurement and randomisation. Those who were on ARBs continued their ARBs. We excluded individuals with diabetes mellitus (ADA criteria), active vasculitis, nephrotic syndrome (\>3gr/24hr urine protein), renal transplantation, fasting total cholesterol \> 7 mmol/L, cholesterol-lowering therapy within three months prior to inclusion or known ischemic cardiac, cerebrovascular or peripheral arterial disease. Ninety-three patients (out of 118 eligible patients) took part in the study and written informed consent was obtained from all participants.


Options:
A: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A
D: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet

Answer: C